Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

James Vasselli; Paul de Souza; Sophia Frentzas; Andrew Weickhardt; Timothy Wyant; Jenny Tang; Aron Knickerbocker; Inbar Amit; Yanay Ofran

Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

James Vasselli
, Paul de Souza
, Sophia Frentzas
, Andrew Weickhardt
, Timothy Wyant
, Jenny Tang
, Aron Knickerbocker
, Inbar Amit
, Yanay Ofran

The Mina and Everard Goodman Faculty of Life Sciences - at Bar-Ilan University

Research output: Contribution to conference › Abstract › peer-review

Original language	English GB
Number of pages	1
State	Published - 3 Jun 2022
Event	American Society of Clinical Oncology (ASCO) Annual Meeting - Duration: 3 Jun 2022 → 7 Jun 2022

Conference

Conference	American Society of Clinical Oncology (ASCO) Annual Meeting
Period	3/06/22 → 7/06/22

Cite this

Vasselli, J., Souza, P. D., Frentzas, S., Weickhardt, A., Wyant, T., Tang, J., Knickerbocker, A., Amit, I., & Ofran, Y. (2022). Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors. Abstract from American Society of Clinical Oncology (ASCO) Annual Meeting.

@conference{2e1bc32b67124afc92445362694ebf1e,

title = "Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors",

author = "James Vasselli and Souza, \{Paul de\} and Sophia Frentzas and Andrew Weickhardt and Timothy Wyant and Jenny Tang and Aron Knickerbocker and Inbar Amit and Yanay Ofran",

year = "2022",

month = jun,

day = "3",

language = "الإنجليزيّة",

note = "American Society of Clinical Oncology (ASCO) Annual Meeting ; Conference date: 03-06-2022 Through 07-06-2022",

}

Vasselli, J, Souza, PD, Frentzas, S, Weickhardt, A, Wyant, T, Tang, J, Knickerbocker, A, Amit, I & Ofran, Y 2022, 'Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors', American Society of Clinical Oncology (ASCO) Annual Meeting, 3/06/22 - 7/06/22.

Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors. / Vasselli, James; Souza, Paul de; Frentzas, Sophia et al.
2022. Abstract from American Society of Clinical Oncology (ASCO) Annual Meeting.

Research output: Contribution to conference › Abstract › peer-review

TY - CONF

T1 - Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

AU - Vasselli, James

AU - Souza, Paul de

AU - Frentzas, Sophia

AU - Weickhardt, Andrew

AU - Wyant, Timothy

AU - Tang, Jenny

AU - Knickerbocker, Aron

AU - Amit, Inbar

AU - Ofran, Yanay

PY - 2022/6/3

Y1 - 2022/6/3

UR - https://scholar.google.com/citations?view_op=view_citation&hl=en&user=xtRXLdkAAAAJ&sortby=pubdate&citation_for_view=xtRXLdkAAAAJ%3AhzvVvKpMvx4C&inst=1200643855431153338

M3 - مختصر

T2 - American Society of Clinical Oncology (ASCO) Annual Meeting

Y2 - 3 June 2022 through 7 June 2022

ER -

Vasselli J, Souza PD, Frentzas S, Weickhardt A, Wyant T, Tang J et al.. Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors. 2022. Abstract from American Society of Clinical Oncology (ASCO) Annual Meeting.

Trial in Progress: A Phase 1-2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients with Advanced Solid Tumors

Conference

Other files and links

Cite this